CMRC Children's Memorial Research Center
Publications, 2002-Present

Hendrix Laboratory, selected publications from 2002-present:

Solicited Contributions (Book Chapters):

Hendrix MJC, Seftor EA, Meltzer PS, Hess AR, Gruman LM, Nickoloff BJ, Miele L, Sheriff DD and Schatteman GC, Bourdon MA and Seftor REB. 2004. The stem cell plasticity of aggressive melanoma tumor cells. In: Germinal Stem Cells, edited by ES Sell. USA: Humana Press chapter 27:297-306.

Hendrix MJC, Luo J, Seftor EA, Sharma N, Heidger PM Jr, Cohen MB, Bhatty R, Chunthapong J, Seftor REB and Lubaroff DM. 2004. Epithelial-mesenchymal interactions in prostatic tumor cell plasticity. In: Cancer Metastasis – Biology and Treatment, edited by RL Ablin and MD Mason. Netherlands: Kluwer Academic Publishers, in press.

Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor REB and Hendrix MJC. 2004. The epigenetic influence of the tumor microenvironment on melanoma plasticity. In: Integration/Interaction of Oncogenic Growth, edited by GG Meadows. Netherlands: Kluwer Academic Publishers, in press.

Hendrix MJC, Seftor EA and Seftor REB. 2004. The plasticity of melanoma cells and associated clinical implications. In: Melanocytes to Melanoma: The progression to malignancy, edited by V Hearing and SPL Leong. USA: Humana Press, in press.

Publications in Refereed Journals:

Seftor EA, Meltzer PS, Kirschmann DA, Pe’er J, Maniotis AJ, Trent JM, Folberg R and Hendrix MJC. 2002. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exper Metast 19:233-246.

Odero-Marah VA, Khalkhali-Ellis Z, Schneider GB, Seftor EA, Seftor REB, Koland JG, and Hendrix MJC. 2002. Tyrosine phosphorylation of maspin in normal mammary epithelia and breast cancer cell lines. BBRC 295:800-805.

Kirschmann DA, Seftor EA, Fong SF, Nieva DRC, Sullivan CM, Edwards EM, Sommer P, Csiszar K and Hendrix MJC. 2002. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62:4478-4483, 2002.

Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA and Hendrix MJC. 2002. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8:2924-2932.

Ray NB, Khalkhali-Ellis Z, Nieva DRC, Seftor EA and Naides SJ. 2002. Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: comment on the article by Ray et al – Reply. Arth Rheum: 2263-2264.

Seftor EA, Meltzer PS, Schatteman GC, Gardner LMG, Hess AR, Kirschmann DA, Seftor REB and Hendrix MJC. 2002. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: Role of vasculogenic mimicry. Crit Rev Oncol Hematol 44:17-27.

Hendrix MJC, Seftor EA, Meltzer PS, Hess AR, Gruman LM, Nickoloff BJ, Miele L, Sheriff DD, Schatteman GC, Bourdon MA and Seftor REB. 2002. The plasticity of aggressive melanoma tumor cells: Recapitulation of an embryonic stem cell program. Recent Adv Res Updates 3:192-200.

Seftor REB, Seftor EA, Kirschmann DA and Hendrix MJC. 2002. Targeting the tumor microenvironment with chemically modified tetracyclines: Inhibition of laminin 52 chain promigratory fragments and vasculogenic mimicry. Molec Cancer Therapeutics 1:1173-1179.

Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA and Hendrix MJC. 2002. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: Implications for anti-vasculogenic therapy. Cancer Biol Therapy 1:661.664.

Seftor REB, Seftor EA, Hess AR and Hendrix MJC. 2003. The role of the vasculogenic phenotype and its associated extracellular matrix in tumor progression: Implications for immune surveillance. Clin Applied Immunol Rev 3:263-276.

Hendrix MJC, Seftor EA, Hess AR and Seftor REB. 2003. The molecular plasticity of human melanoma cells. Oncogene Rev 22:3070-3075.

Hendrix MJC, Seftor EA, Hess AR and Seftor REB. 2003. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nature Rev Cancer 3:411-421.

Hendrix MJC, Seftor EA, Kirschmann DA, Quaranta V and Seftor REB. 2003. Remodeling the microenvironment by aggressive melanoma tumor cells. Annals NY Acad Sci 995:151-161.

Odero-Marah V, Khalkhali-Ellis Z, Seftor EA, Seftor REB and Hendrix MJC. 2003. Maspin regulates cell motility through the RAC signaling pathway. Cancer Biol & Therapy 2:67-72.

Hess AR, Seftor EA, Seftor REB and Hendrix MJC. 2003. Phosphoinositide 3-kinase regulates membrane type-1 matrix metalloproteinase (MT1-MMP) and MMP-2 activity during melanoma cell vasculogenic mimcry. Cancer Res. 63:4757-4762.

Ruf W, Seftor EA, Prtrovan R, Weiss RM, Gruman LM, Margaryan NV, Seftor REB, Miyagi Y and Hendrix MJC. 2003. Differential role of tissue factor pathway inhibitors-1 and 2 (TFPI-1 and 2) in melanoma vasculogenic mimicry. Cancer Res 63:5381-5389.

Chunthapong J, Seftor EA, Khalkhali-Ellis Z, Seftor REB, Amir S, Lubaroff DM, Heidger PM Jr. and Hendrix MJC. 2004. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem 91:649-661.

Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJC. 2004. Functional roles of matrix metalloproteinases in ovarian tumor cell plasticity. Amer J Obstet Gyn 190:899-909.

Futscher BW, O’Meara MM, Lu D, Rennels R, Gruman LM, Seftor REB, Hendrix MJC and Domann FE. 2004. Epigenetic changes in the maspin promoter precede malignant transformation in human breast cancer. Neoplasia 6(4):380-389.

Qin J-Z, Stennett L, Bacon P, Bodner B, Hendrix MJC, Seftor REB, Seftor EA, Margaryan NV, Pollock P, Curtis A, Trent JM, Bennett F,, Miele L and Nickoloff BJ. 2004. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Molec Cancer Ther 3:895-902. 


van der Schaft, D.W.J., Seftor, R.E.B., Seftor, E.A., Hess, A.R., Gruman, L.M., Kirschmann, D.A., Yokoyama, Y., Griffioen, A.W. and Hendrix, M.J.C. 2004. Differential effects of angiogenesis inhibitors on vascular network formation by endothelial and melanoma cells. J. Natl. Cancer Inst. 96(19):1473-1477.

Manuscripts in Press:

Rojas JD, Souad S, Martinez GM, Bakunts K, Meininger CJ, Wu G, Wesson DE, Seftor EA, Hendrix MJC and Martinez-Zaguilan R. 2004. Plasmelemmal vacuolar H+-ATPase is decreased in microvascular endothelial cells from a diabetic model. J Cell Physiol.

Manuscripts in Revision: 

Seftor, E.A., Meltzer, P.S., Kirschmann, D.A., Margaryan, N.V., Nickoloff, B.J., Seftor, R.E.B. and Hendrix, M.J.C. The epigenetic reprogramming of poorly aggressive melanoma cells and melanocytes by a metastatic melanoma microenvironment. Cancer Cell, submitted October, 2004.